Cargando…
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditiona...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989110/ https://www.ncbi.nlm.nih.gov/pubmed/33815569 http://dx.doi.org/10.1177/1756284821999902 |
_version_ | 1783668896125943808 |
---|---|
author | Facchin, Sonia Buda, Andrea Cardin, Romilda Agbariah, Nada Zingone, Fabiana De Bona, Manuela Zaetta, Debora Bertani, Lorenzo Ghisa, Matteo Barberio, Brigida Savarino, Edoardo Vincenzo |
author_facet | Facchin, Sonia Buda, Andrea Cardin, Romilda Agbariah, Nada Zingone, Fabiana De Bona, Manuela Zaetta, Debora Bertani, Lorenzo Ghisa, Matteo Barberio, Brigida Savarino, Edoardo Vincenzo |
author_sort | Facchin, Sonia |
collection | PubMed |
description | Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test (k-coefficient = 0.84). |
format | Online Article Text |
id | pubmed-7989110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-79891102021-04-02 Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients Facchin, Sonia Buda, Andrea Cardin, Romilda Agbariah, Nada Zingone, Fabiana De Bona, Manuela Zaetta, Debora Bertani, Lorenzo Ghisa, Matteo Barberio, Brigida Savarino, Edoardo Vincenzo Therap Adv Gastroenterol Case Series Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test (k-coefficient = 0.84). SAGE Publications 2021-03-21 /pmc/articles/PMC7989110/ /pubmed/33815569 http://dx.doi.org/10.1177/1756284821999902 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Series Facchin, Sonia Buda, Andrea Cardin, Romilda Agbariah, Nada Zingone, Fabiana De Bona, Manuela Zaetta, Debora Bertani, Lorenzo Ghisa, Matteo Barberio, Brigida Savarino, Edoardo Vincenzo Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients |
title | Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients |
title_full | Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients |
title_fullStr | Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients |
title_full_unstemmed | Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients |
title_short | Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients |
title_sort | rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with elisa and potential for improving therapeutic drug monitoring in ibd patients |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989110/ https://www.ncbi.nlm.nih.gov/pubmed/33815569 http://dx.doi.org/10.1177/1756284821999902 |
work_keys_str_mv | AT facchinsonia rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT budaandrea rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT cardinromilda rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT agbariahnada rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT zingonefabiana rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT debonamanuela rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT zaettadebora rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT bertanilorenzo rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT ghisamatteo rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT barberiobrigida rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients AT savarinoedoardovincenzo rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients |